Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing gefitinib and histone deacetylase inhibitor, lipidosome preparation of pharmaceutical composition, and pharmaceutical application of pharmaceutical composition and lipidosome preparation

A technology of deacetylase and gefitinib, applied in the field of biomedicine, can solve the problems of narrow therapeutic window, failure of molecular targeted therapy, and limited clinical benefit, and achieve the effect of improving accumulation

Active Publication Date: 2019-05-14
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, 50% of patients will undergo a mutation from threonine (T) to methionine (M) at the 790th amino acid on exon 20 after receiving treatment, resulting in the ability of EGFR to bind ATP Significantly enhanced, resistance to gefitinib, resulting in failure of molecular targeted therapy
Although the second-generation TKI afatinib was later developed, which is an irreversible inhibitor, it cannot effectively control EGFR due to its narrow therapeutic window. T790M Drug resistance due to mutation, limited clinical benefit
In March 2017, the third-generation TKI osimertinib was approved for marketing in China. It targets EGFR T790M The resulting drug-resistant patients have significant clinical benefits. However, it has been widely reported that EGFR C797S mutations will occur after patients receive osimertinib treatment, and they are resistant to osimertinib.
[0007] However, for the combined use of molecularly targeted drugs, there are few studies on dosage form modification in pharmacy, and the monoclonal antibody Herceptin is used as a targeting ligand to modify the surface of the drug delivery system with HER2 as the target in non-small cell lung cancer. research has not yet been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing gefitinib and histone deacetylase inhibitor, lipidosome preparation of pharmaceutical composition, and pharmaceutical application of pharmaceutical composition and lipidosome preparation
  • Pharmaceutical composition containing gefitinib and histone deacetylase inhibitor, lipidosome preparation of pharmaceutical composition, and pharmaceutical application of pharmaceutical composition and lipidosome preparation
  • Pharmaceutical composition containing gefitinib and histone deacetylase inhibitor, lipidosome preparation of pharmaceutical composition, and pharmaceutical application of pharmaceutical composition and lipidosome preparation

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0068] Preparation of dual-targeted co-loaded liposomes

[0069] (a) Weigh an appropriate amount of mannose isothiocyanate and dissolve it in dichloromethane, add an appropriate amount of triethylamine to adjust the pH to alkaline, and use mannose isothiocyanate / DSPE-PEG 2000 -NH 2 The molecular ratio is 3 / 1, and then add an appropriate amount of DSPE-PEG to it 2000 -NH 2 , react at room temperature for 4 hours, remove the organic solvent by rotary evaporation, add an appropriate amount of water, shake well, centrifuge at 15,000 rpm for 5 minutes, take the supernatant and freeze-dry to obtain mannose-modified DSPE-PEG 2000 , call it DSPE-PEG 2000 -Man.

[0070] (b) Weigh egg yolk lecithin (PC 98T), cholesterol, DSPE-PEG 2000 、DSPE-PEG 2000 -Man and DSPE-PEG 2000 -NHS was dissolved in chloroform and added to the round bottom flask according to the molecular ratio of 10 / 2 / 1 / 0.1 / 0.1. Weigh gefitinib and vorinostat, dissolve them in methanol, add them into a round bottom f...

experiment Embodiment 1

[0090] in vitro cellular uptake

[0091] The green fluorescent probe coumarin 6 was introduced into liposomes at a mass ratio of gefitinib / coumarin 6 of 10 / 1 to prepare dual-targeted co-drug-loaded lipids loaded with coumarin 6 Plastids and unmodified drug-loaded liposomes, using a fluorescence spectrophotometer to quantify the coumarin 6 contained in the liposomes under the condition of an excitation wavelength of 466nm and an emission wavelength of 504nm, the amount of coumarin 6 entering the cell To characterize the cell entry efficiency of liposomes. details as follows:

[0092] HER2-positive cell line H1975 and M2 macrophages were used at 8x10 per well 4 Cells were seeded in a 12-well cell culture plate at 37°C, 5% CO 2 After culturing under the same conditions for 24 hours, 0.1 μg of coumarin 6 per well was added to dual-targeted co-drug-loaded liposomes and unmodified co-drug-loaded liposomes. Cells were collected after liposome treatment for 4 hours for flow cytomet...

experiment Embodiment 2

[0095] In vitro antitumor activity

[0096] The in vitro toxicity of drugs and dual-targeted co-loaded liposomes in HER2-positive H1975 cells was detected by MTT method to characterize the impact of targeted modification and co-loading on the synergistic efficiency of combined drugs. The specific experiment is as follows:

[0097] at 5x10 3 Cells per well were planted in a 96-well plate at a density of 37°C, 5% CO 2After culturing for 24 hours under the same conditions, the cells were treated with different concentrations of gefitinib (the mass ratio of vorinostat to gefitinib was 0.12:1, and the mass ratio of TMP 195 to gefitinib was 1:1). Set up 6 auxiliary wells, and set up a negative control without drug addition at the same time. After culturing for 48 hours, 20 μL of 5 mg / mL MTT solution was added to each well, and cultured for another 4 hours. The liquid in each well was removed with a syringe, and 200 μL of dimethyl sulfoxide was added to each well. For the absorba...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to a pharmaceutical composition containing a gefitinib and histone deacetylase inhibitor, a lipidosome preparation of the pharmaceutical composition, and application of the pharmaceutical composition and the lipidosome preparation to preparing medicines for treating the EGFRT790M mutation drug-fast non-small cell lung cancer. The histone deacetylase inhibitor is preferentially Vorinostat and TMP195. Particularly, the invention further relates to a double-target co-carrier liposome, wherein the surface of the liposome is modified by herceptin and mannose, and the liposomecontains the pharmaceutical composition. The double-target co-carrier liposome can be used for controlling the macrophage polarization and can be used for treating the non-small cell lung cancer withEGFRT790M mutation.

Description

technical field [0001] The invention belongs to the field of biomedicine, more specifically, the invention relates to a pharmaceutical composition comprising gefitinib and a histone deacetylase inhibitor, its liposome preparation and their preparation for the treatment of EGFR T790M Use of a drug in mutation-resistant non-small cell lung cancer. Background technique [0002] Lung cancer is a type of cancer with the highest morbidity and mortality in China and even in the world. With the intensification of my country's industrialization and urbanization process, resulting in serious air pollution and high smoking rate, the harm of lung cancer will be further aggravated. Among all malignant tumors, lung cancer is one of the most deeply studied pathogenesis. The main cause of non-small cell lung cancer (NSCLC) is the deletion of the 19th exon or the 21st exon of the epidermal growth factor receptor (EGFR). The 858th amino acid on the exon is mutated from leucine (L) to argini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5377A61K31/167A61K9/127A61P37/02A61P35/00
Inventor 黄永焯彭会歌
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com